|Bid||65.00 x 1400|
|Ask||69.99 x 800|
|Day's Range||66.25 - 67.29|
|52 Week Range||45.31 - 69.71|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 25, 2018 - Jul 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||67.33|
Seattle Genetics, Inc. (SGEN) today announced dosing of the first patient in the phase 2 innovaTV 204 clinical trial evaluating the efficacy, safety and tolerability of tisotumab vedotin as monotherapy for patients with recurrent and/or metastatic cervical cancer who have relapsed or progressed after standard of care treatment. Tisotumab vedotin is an investigational antibody-drug conjugate (ADC) designed to target Tissue Factor antigen on cancer cell surfaces and deliver the cell-killing agent monomethyl auristatin E (MMAE) directly inside cancer cells. The Tissue Factor antigen target is overexpressed in the vast majority of patients with cervical cancer and in many other solid tumors, including ovarian, lung, pancreatic, colorectal and head and neck.
On Wednesday, June 06, 2018, US markets saw broad based gains with eight out of nine sectors finishing the trading sessions in green. All you have to do is sign up today for this free limited time offer by clicking the link below.
Seattle Genetics, Inc. announced today that management will present at the Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June 13, 2018 at 1:20 p.m.
Seattle Genetics, Inc. today highlighted data from the phase 3 ECHELON-1 clinical trial evaluating ADCETRIS in combination with chemotherapy in newly diagnosed stage III or IV classical Hodgkin lymphoma at the 2018 American Society of Clinical Oncology Annual Meeting being held June 1-5 in Chicago, Illinois.
Seattle Genetics, Inc. (SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the presentation of updated phase 1 data of enfortumab vedotin, an investigational antibody-drug conjugate (ADC), at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting in Chicago. In this phase 1 study (EV-101), enfortumab vedotin was evaluated as monotherapy for patients with metastatic urothelial cancer including patients who previously received a checkpoint inhibitor. This phase 1 study is part of a broader program focused on investigating enfortumab vedotin in both monotherapy and in combination with a checkpoint inhibitor for locally advanced or metastatic urothelial cancer.
-Updated Data from Phase 1 EV-101 Study Highlighted in ASCO 2018 Oral Presentation Support Rapid Development Program and Ongoing Pivotal Study- TOKYO and BOTHELL, Wash. , June 3, 2018 /PRNewswire/ -- ...
Biotech stocks are one of the hottest sectors in the stock market, as measured by the SPDR S&P Biotech ETF ( XBI). If the sector is to continue to rise, it will take stocks such as Spark Therapeutics Inc. ( ONCE), Intercept Pharmaceuticals Inc. ( ICPT), and Seattle Genetics Inc. ( SGEN) to help it rise.
NEW YORK, NY / ACCESSWIRE / June 1, 2018 / U.S. markets closed sharply lower on Thursday as the U.S. decided to impose tariffs on steel and aluminum imports from Canada, Mexico and the European Union. ...
Incyte (INCY) has a well-established distribution network in the United States and sells its products Jakafi and Iclusig in the United States through its own network.
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In December 2017, CRISPR Therapeutics (CRSP) entered a collaboration with Vertex Pharmaceuticals (VRTX) for the co-development and co-commercialization of CTX001. CRISPR Therapeutics submitted a CTA (clinical trial application) for CTX001 for the initiation of phase 1/2 trial for the evaluation of the safety and efficacy in the treatment of beta-thalassemia in Europe. CRISPR Therapeutics plans to submit an Investigational New Drug application to the FDA for the approval of an initiation of phase 1/2 clinical trial in the US for the treatment of sickle cell disease in the second half of 2018.
Seattle Genetics, Inc. (SGEN) today announced the appointment of Roger D. Dansey, M.D., as Chief Medical Officer. Dr. Dansey brings extensive experience in cancer drug development, most recently from Merck Inc. where he was Therapeutic Area Head for Late Stage Oncology, responsible for the ongoing registration efforts for KEYTRUDA® (pembrolizumab) across multiple tumor types. “Roger’s appointment reflects the growing importance of late-stage clinical drug development at Seattle Genetics as we transition to a global, multi-product oncology company,” said Clay Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics.
Seattle Genetics, Inc. today announced that multiple abstracts from its robust clinical development portfolio will be presented at the upcoming 2018 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, from June 1-5, 2018.
Biotech stocks are breaking out, with the SPDR S&P Biotech ETF ( XBI) gearing up for what could be a significant rise higher. Since that time the group has turned higher, and now technical analysis suggests more gains may lie ahead for the sector.
NEW YORK, May 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Patterson ...
LONDON, UK / ACCESSWIRE / May 4, 2018 / If you want access to our free research report on Cellectar Biosciences, Inc. (NASDAQ: CLRB) ("Cellectar") all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CLRB as the Company's latest news hit the wire. On May 02, 2018, the Company announced that the US Food and Drug Administration (FDA) has granted a Rare Pediatric Disease Designation (RPDD) to its lead phospholipid drug conjugate, CLR 131, for the treatment of neuroblastoma. Active-Investors.com is currently working on the research report for Seattle Genetics, Inc. (NASDAQ: SGEN), which also belongs to the Healthcare sector as the Company Cellectar Biosciences.
Bothell's future as a thriving biotech hub hinges on its ability to compete with Seattle's Lake Union area. That's prompting changes that aim to make Bothell's business district a great place to work and play.
Seattle Genetics, Inc. announced today that management will present at the Bank of America Merrill Lynch Health Care Conference 2018 on Tuesday, May 15, 2018 at 5:00 p.m.
The company is the state's largest biotech, and has been growing quickly. Now, it's on the hunt for another building. Seattle Genetics is looking for a building that includes office and lab space. The company will likely remodel the new building.
On a per-share basis, the Bothell, Washington-based company said it had a loss of 73 cents. Losses, adjusted for non-recurring costs, were 61 cents per share. The results did not meet Wall Street expectations. ...
Seattle Genetics, Inc. today reported financial results for the first quarter ended March 31, 2018. The company also highlighted ADCETRIS commercialization and clinical development accomplishments, and progress with its late-stage clinical programs and pipeline of targeted therapies for cancer.